Versant Capital Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.23M | Sell |
73,361
-5,343
| -7% | -$307K | 0.38% | 44 |
|
|
2026
Q1 | $4.77M | Buy |
78,704
+3,526
| +5% | +$206K | 0.47% | 33 |
|
|
2025
Q4 | $4.06M | Sell |
75,178
-5,442
| -7% | -$262K | 0.51% | 32 |
|
|
2025
Q3 | $3.64M | Buy |
80,620
+5,737
| +8% | +$268K | 0.49% | 34 |
|
|
2025
Q2 | $3.47M | Sell |
74,883
-6,465
| -8% | -$317K | 0.53% | 31 |
|
|
2025
Q1 | $4.96M | Buy |
81,348
+2,658
| +3% | +$155K | 0.83% | 23 |
|
|
2024
Q4 | $4.45M | Buy |
78,690
+9,692
| +14% | +$542K | 0.96% | 20 |
|
|
2024
Q3 | $3.57M | Buy |
68,998
+386
| +0.6% | +$18.1K | 0.81% | 25 |
|
|
2024
Q2 | $2.85M | Buy |
68,612
+176
| +0.3% | +$7.88K | 0.72% | 26 |
|
|
2024
Q1 | $3.71M | Sell |
68,436
-918
| -1% | -$46.8K | 1.06% | 19 |
|
|
2023
Q4 | $3.56M | Sell |
69,354
-124
| -0.2% | -$6.51K | 1.06% | 20 |
|
|
2023
Q3 | $4.03M | Buy |
69,478
+25
| +0% | +$1.53K | 1.28% | 18 |
|
|
2023
Q2 | $4.44M | Buy |
69,453
+27
| +0% | +$1.81K | 1.42% | 17 |
|
|
2023
Q1 | $4.81M | Buy |
69,426
+918
| +1% | +$64.7K | 1.62% | 14 |
|
|
2022
Q4 | $4.93M | Sell |
68,508
-480
| -0.7% | -$36.2K | 1.78% | 14 |
|
|
2022
Q3 | $4.9M | Hold |
68,988
| – | – | 1.92% | 12 |
|
|
2022
Q2 | $5.31M | Sell |
68,988
-15
| -0% | -$1.14K | 1.95% | 13 |
|
|
2022
Q1 | $5.04M | Sell |
69,003
-12
| -0% | -$806 | 1.61% | 16 |
|
|
2021
Q4 | $4.3M | Sell |
69,015
-6
| -0% | -$352 | 1.4% | 17 |
|
|
2021
Q3 | $4.08M | Sell |
69,021
-14,060
| -17% | -$926K | 1.44% | 17 |
|
|
2021
Q2 | $5.55M | Sell |
83,081
-5
| -0% | -$326 | 2.05% | 12 |
|
|
2021
Q1 | $5.25M | Hold |
83,086
| – | – | 1.91% | 11 |
|
|
2020
Q4 | $5.15M | Sell |
83,086
-3
| -0% | -$184 | 2.03% | 11 |
|
|
2020
Q3 | $5.01M | Buy |
83,089
+11
| +0% | +$662 | 2.23% | 13 |
|
|
2020
Q2 | $4.88M | Sell |
83,078
-9
| -0% | -$538 | 2.24% | 13 |
|
|
2020
Q1 | $4.63M | Sell |
83,087
-148
| -0.2% | -$9.05K | 2.44% | 11 |
|
|
2019
Q4 | $5.34M | Buy |
83,235
+173
| +0.2% | +$9.91K | 2.69% | 10 |
|
|
2019
Q3 | $4.21M | Buy |
83,062
+52
| +0.1% | +$2.44K | 1.98% | 13 |
|
|
2019
Q2 | $3.76M | Sell |
83,010
-819
| -1% | -$38.1K | 1.72% | 16 |
|
|
2019
Q1 | $4M | Sell |
83,829
-1,210
| -1% | -$60.3K | 1.71% | 16 |
|
|
2018
Q4 | $4.42M | Hold |
85,039
| – | – | 2.04% | 15 |
|
|
2018
Q3 | $5.28M | Sell |
85,039
-52
| -0.1% | -$3.09K | 2.16% | 12 |
|
|
2018
Q2 | $4.71M | Sell |
85,091
-69
| -0.1% | -$3.73K | 1.98% | 15 |
|
|
2018
Q1 | $5.39M | Sell |
85,160
-836
| -1% | -$53.8K | 2.22% | 11 |
|
|
2017
Q4 | $5.27M | Buy |
85,996
+500
| +0.6% | +$31.3K | 2.13% | 11 |
|
|
2017
Q3 | $5.45M | Sell |
85,496
-59
| -0.1% | -$3.44K | 2.97% | 7 |
|
|
2017
Q2 | $4.77M | Sell |
85,555
-84
| -0.1% | -$4.57K | 2.63% | 9 |
|
|
2017
Q1 | $4.66M | Buy |
85,639
+106
| +0.1% | +$5.81K | 2.58% | 9 |
|
|
2016
Q4 | $5M | Sell |
85,533
-232
| -0.3% | -$12.7K | 2.85% | 7 |
|
|
2016
Q3 | $4.62M | Buy |
85,765
+36
| +0% | +$2.31K | 2.63% | 9 |
|
|
2016
Q2 | $6.3M | Buy |
85,729
+5
| +0% | +$353 | 3.72% | 6 |
|
|
2016
Q1 | $5.48M | Buy |
85,724
+3
| +0% | +$189 | 3.31% | 6 |
|
|
2015
Q4 | $5.9M | Buy |
+85,721
| New | +$5.66M | 3.69% | 6 |
|
Other funds holding BMY
LMFP
AIM
FWIA
DLA
Versant Capital Management's BMY Position: Q2 2026 in Review
Versant Capital Management reduced its Bristol-Myers Squibb (BMY) stake by 6.8% in Q2 2026, selling an estimated $307K and leaving 73,361 shares worth $4.23M. The position accounts for 0.38% of the portfolio, ranked #44.
Versant Capital Management first reported a position in BMY in Q4 2015 and has held it in 43 quarters since. The position peaked at $6.3M in Q2 2016. 679 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Versant Capital Management held 73,361 shares of Bristol-Myers Squibb worth $4.23M as of Q2 2026.
- Versant Capital Management sold 5,343 Bristol-Myers Squibb shares in Q2 2026, an estimated $307K.
- Bristol-Myers Squibb made up 0.38% of Versant Capital Management's portfolio in Q2 2026, its #44 holding.
- Versant Capital Management first reported a position in Bristol-Myers Squibb in Q4 2015 and has held it in 43 quarters since.
- Versant Capital Management's Bristol-Myers Squibb position peaked at $6.3M in Q2 2016.
- 679 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.